Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches

Molecular and Cellular Endocrinology

Volumn 197, Issue 1-2, 2002, Pages 239-250

  Van Moorselaar, R J A ^a   Voest, E E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Prostate cancer; Review

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; A 177430; ANGIOGENESIS INHIBITOR; ANGIOTENSIN; BATIMASTAT; CURCUMIN; CYCLOOXYGENASE 2; DOCETAXEL; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERFERON; INTERLEUKIN 10; MARIMASTAT; METALLOPROTEINASE; MONOCLONAL ANTIBODY LM 609; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RETINOID; ROQUINIMEX; SEMAXANIB; THALIDOMIDE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; GROWTH PROMOTOR;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL INTERACTION; CELL PROLIFERATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HUMAN; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; DISEASE COURSE; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; GROWTH SUBSTANCES; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 0037195506     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00262-9     Document Type: Review

References (121)

1. Abdulkadir S.A., Carvalhal G.F., Kaleem Z., Kisiel W., Humphrey P.A., Catalona W.J., Milbrandt J. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum. Pathol. 31:2000;443-447.
2. Adolfsson J., Steineck G., Hedlund P.O. Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup. J. Urol. 161:1998;505-508.
3. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 59:1992;115-165.
4. Bauer K.S., Figg W.D., Hamilton J.M., Jones E.C., Premkumar A., Steinberg S.M., Dyer V., Linehan W.M., Pluda J.M., Reed E. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer. Clin. Cancer Res. 5:1999;2324-2329.
5. Bergh J.C.S., Totterman T.H., Termander B.C., Strandgarden K.A., Gunna P.O., Nilsson B.I. The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects. Cancer Invest. 15:1997;204-211.
6. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
7. Bok R.A., Halabi S., Fei D.T., Rodriquez C.R., Hayes D.F., Vogelzang N.J., Kantoff P., Shuman M.A., Small E.J. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 61:2001;2533-2536.
8. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130:1995;503-506.
9. Borre M., Nerstrøm B., Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin. Cancer Res. 6:2000;1882-1890.
10. 3 for angiogenesis. Science. 264:1994;569-571.
11. Campbell S.C. Advances in angiogenesis research: relevance to urological oncology. J. Urol. 158:1997;1633-1674.
12. Ching K.Z., Ramsey E., Pettigrew N., D'Cunha R., Jason M., Dodd J.G. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol. Cell Biochem. 126:1993;151-158.
13. Cvetkovic D., Movsas B., Dicker A.P., Hanlon A.L., Greenberg R.E., Chapman J.D., Hanks G.E., Tricoli J.V. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology. 57:2001;821-825.
14. Daliani D.D., Eisenberg P.D., Weems J., Lord R., Fueger R., Logothetis C.J. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus α-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J. Urol. 153:1995;1587-1591.
15. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:1994;4082-4085.
16. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., Tomaszewski J.E., Renshaw A.A., Kaplan I., Beard C.J., Wein A.J. Biochemical outcome after radical prostatectomy, external beam radiation, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
17. Debruyne F.M.J., Murray R., Fradet Y., Johansson J.E., Tyrrell C., Boccardo F., Denis L., Marberger J.M., Brune D., Rassweiler J., Vangeneugden T., Bruynseels J., Janssens M., De Porre P. Liarozole - a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology. 52:1998;72-81.
18. Dijkman G.A., van Moorselaar R.J.A., van Ginckel R., van Stratum P., Wouters L., Debruyne F.M.J., Schalken J.A., de Coster R. Antitumoral effects of Liarozole in androgen-dependent and -independent R3327-Dunning prostate adenocarcinomas. J. Urol. 151:1994;217-222.
19. Doll J.A., Reiher F.K., Crawford S.E., Pins M.R., Campbell S.C., Bouck N.P. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate. 49:2001;293-305.
20. Dong Z., Greene G., Pettaway C., Dinney C.P.N., Eue I., Lu W., Bucana C.D., Balbay M.D., Bielenburg D., Fidler I.J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β Cancer Res. 59:1999;872-879.
21. Dorai T., Cao Y.-C., Dorai B., Buttyan R., Katz A.E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. 47:2001;293-303.
22. Dow J.K., deVere White R.W. Fibroblast growth factor 2: its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions. Urology. 55:2000;800-806.
23. Duque J.L.F., Loughlin K.R., Adam R.M., Kantoff P.W., Zurakowski D., Freeman M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 54:1999;523-527.
24. Falcone A., Antonuzzo A., Danesi R., Allegrini G., Monica L., Pfanner E., Masi G., Ricci S., Del Tacca M., Conte P. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer. 86:1999;470-476.
25. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
26. Ferrer F.A., Miller L.J., Lindquist R., Kowalczyk P., Laudone V.P., Albertsen P.C., Kreutzer D.L. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology. 54:1999;567-572.
27. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
28. Figg W.D., Dahut W., Duray P., Hamilton M., Tompkins A., Steinberg S.M., Jones E., Premkumar A., Linehan W.M., Floeter M.K., Chen C.C., Dixon S., Kohler D.R., Krüger E.A., Gubish E., Pluda J.M., Reed E. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7:2001a;1888-1893.
29. Figg W.D., Arlen P., Gulley J., Fernandez P., Noone M., Fedenko K., Hamilton M., Parker C., Kruger E.A., Pluda J., Dahut W.L. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Sem. Oncol. 28:(Suppl. 15):2001b;62-66.
30. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1971;1182-1186.
31. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:1989;58-61.
32. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
33. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:1995;27-31.
34. Fortier A.H., Nelson B.J., Grella D.K., Holaday J.W. Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91:1999;1635-1640.
35. Garcia-Schürmann J.M., Schulze H., Haupt G., Pastor J., Allolio B., Senge T. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer. Urology. 53:1999;535-541.
36. Gately S., Twardowski P., Stack M.S., Patrick M., Boggio L., Cundiff D.L., Schnaper H.W., Madison L., Volpert O., Bouck N., Enghild J., Kwaan H.C., Soff G.A. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56:1996;4887-4890.
37. Giordano F.J., Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Gen. Dev. 11:2001;35-40.
38. 3. Clin. Cancer Res. 6:2000;3056-3061.
39. Häggström S., Franck Lissbrant I., Bergh A., Damber J.-E. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J. Urol. 161:1999;1620-1625.
40. Hamdy F.C., Thomas B.G. New therapeutic concepts in prostate cancer. BJU Int. 88:(Suppl. 2):2001;43-48.
41. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
42. Hegarty N.J., Fitzpatrick J.M., Richie J.P., Scardino P.T., deVere White R.W., Schröder F.H., Coffey D.S. Future prospects in prostate cancer. Prostate. 40:1999;261-268.
43. Heidtmann H.-H., Nettelbeck D.M., Mingels A., Jäger R., Welker H.-G., Kontermann R.E. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br. J. Cancer. 81:1999;1269-1273.
44. Höckel M., Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28:(Suppl. 8):2001;36-41.
45. 125Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J. Urol. 130:1983;283-286.
46. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1:1995;149-153.
47. Horti J., Dixon S.C., Logothetis C.J., Guo Y., Reed E., Figg W.D. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br. J. Cancer. 79:1999;1588-1593.
48. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer. 85:2000;60-67.
49. Huang S., Pettaway C.A., Uehara H., Bucana C.D., Fidler I.J. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene. 20:2001;4188-4197.
50. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
51. Huss W.J., Hanrahan C.F., Barrios R.J., Simons J.W., Greenberg N.M. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 61:2001;2736-2743.
52. Inoue K., Slaton J.W., Eve B.Y., Kim S.J., Perrotte P., Balbay M.D., Yano S., Bar-Eli M., Radinsky R., Pettaway C.A., Dinney C.P.N. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6:2000;2104-2119.
53. Izawa J.I., Dinney C.P.N. The role of angiogenesis in prostate and other urological cancers: a review. CMAJ. 164:2001;662-670.
54. Jin R.J., Kwak C., Lee S.G., Lee C.H., Soo C.G., Park M.S., Lee E., Lee S.E. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts. Cancer Gene Ther. 7:2000;1537-1542.
55. Jones A., Fujiyama C. Angiogenesis in urological malignancy: prognostic indicator and therapeutic target. BJU Int. 83:1999;535-556.
56. Joseph I.B.J.K., Nelson J.B., Denmeade S.R., Isaacs J.T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res. 3:1997;2507-2511.
57. Kenyon B.M., Browne F., D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64:1997;971-978.
58. Kerbel R.S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J. Clin. Oncol. 19:2001;45s-51s.
59. Kim I.Y., Ahn H.J., Lang S., Oefelein M.G., Oyasu R., Kozlowski J.M., Lee C. Loss of expression of transforming growth factor-β receptors type I and II correlates with poor prognosis in prostate cancer patients. Clin. Cancer Res. 4:1998;1625-1630.
60. Kim S.J., Uehara H., Karashina T., Mccarty M., Shih N., Fidler I.J. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 3:2001;33-42.
61. Kirschenbaum A., Klausner A.P., Lee R., Unger P., Yao S., Liu X.-H., Levine A.C. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 56:2000;671-676.
62. Kirschenbaum A., Liu X.-H., Yao S., Levine A.C. The role of cyclooxygenase-2 in prostate cancer. Urology. 58:(Suppl. 2A):2001;127-131.
63. Koop E.A., Voest E.E. Tumor vasculature as a target. Anticancer Drug Dev. 2002;123-136.
64. Krupski T., Petroni G.R., Frierson H.F., Theodorescu D. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology. 55:2000;743-749.
65. Kuniyasu H., Troncoso P., Johnston D., Bucana C.D., Tahara E., Fidler I.J., Pettaway C.A. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res. 6:2000;2295-2308.
66. Kuratsukuri K., Nishisaka N., Jones R.F., Wang C.Y., Haas G.P. Clinical trials of immunotherapy for advanced prostate cancer. Urol. Oncol. 5:2000;265-273.
67. La Rocca R.V., Danesi R., Cooper M.R., Jamis-Dow C.A., Ewing M.W., Linehan W.M., Myers C.E. Effect of suramin on human prostate cancer cells in vitro. J. Urol. 145:1991;393-398.
68. Laird A.D., Vajkoczy P., Shawver L.K., Thurnher A., Liang C., Mohammadi M., Schlessinger J., Ullrich A., Hubbard S.R., Blake R.A., Fong T.A., Strawn L.M., Sun L., Tang C., Hawtin R., Tang F., Shenoy N., Hirth K.P., McMahon G., Cherrington J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:2000;4152-4160.
69. Lee C., Sintich S.M., Mathews E.P., Shah A.H., Kundu S.D., Perry K.T., Seon Cho J., Ilio K.Y., Cronauer M.V., Janulis L., Sensibar J.A. Transforming growth factor-β in benign and malignant prostate. Prostate. 39:1999;285-290.
70. Lein M., Jung K., Le D.K., Hasan T., Ortel B., Borchert D., Winkelmann B., Schnorr D., Loenings S.A. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate. 43:2000;77-82.
71. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164:2000;820-825.
72. Logothetis C.J., Wu K.K., Finn L.D., Daliani D., Figg W., Ghaddar H., Gutterman J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7:2001;1198-1203.
73. Los M., Voest E.E. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin. Oncol. 28:2001;93-105.
74. Maffezzini M., Simonato A., Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (α-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate. 28:1996;282-286.
75. Mehta R., Kyshtoobayeva A., Kurosaki T., Small E.J., Kim H., Stroup R., McLaren C.E., Li K.-T., Fruehauf J.P. Independent association of angiogenesis index with outcome in prostate cancer. Clin. Cancer Res. 7:2001;81-88.
76. Melnyk O., Zimmerman M., Kim K.J., Shuman M. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J. Urol. 161:1999;960-963.
77. Mendel D.B., Schreck R.E., West D.C., Li G., Strawn L.M., Tanciongco S.S., Vasile S., Shawver L.K., Cherrington J.M. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 6:2000;4848-4858.
78. Miller K.D., Sweeney C.J., Sledge G.W. Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19:2001;1195-1206.
79. Miller W.H. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer. 83:1998;1471-1482.
80. Montironi R., Diamanti L., Thompson D., Bartels H.G., Bartels P.H. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur. Urol. 30:1996;191-200.
81. Moul J.D. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur. Urol. 35:1999;399-407.
82. Nakamoto T., Chang C., Li A., Chodak G.W. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 52:1992;571-577.
83. Nemunaitis J., Poole C., Primrose J., Rosemurgy A., Malfetano J., Brown P., Berrington A., Cornish A., Lynch K., Rasmusen H., Kerr D., Cox D., Millar A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor Marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4:1998;1101-1109.
84. Nie D., Tang K., Szekeres K., Li L., Honn K.V. Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications. Ann. N.Y. Acad. Sci. 905:2000;165-176.
85. Okada K., Yokoyama K., Okihara K., Ukimura O., Kojima M., Miki T., Takamatsu T. Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate. Urology. 57:2001;376-381.
86. Olson K.A., Byers H.R., Key M.E., Fett J.W. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin. Cancer Res. 7:2001;3598-3605.
87. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:1994;315-328.
88. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:1996;689-692.
89. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
90. Pal S., Iruela-Arispe M.L., Harvey V.S., Zeng H., Nagy J.A., Dvorak H.F., Mukhopadhyay D. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Microvasc. Res. 60:2000;112-120.
91. Papadopoulos I., Sivridis E., Giatromanolaki A., Koukourakis M.I. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin. Cancer Res. 7:2001;1533-1538.
92. Pasquali D., Thaller C., Eichele G. Abnormal level of retinoic acid in prostate cancer tissues. J. Clin. Endocrinol. Metab. 81:1996;2186-2191.
93. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21:2001;1104-1107.
94. Petrylak D.P. Docetaxel (taxotere) in hormone-refractory prostate cancer. Sem. Oncol. 27:(Suppl. 3):2000;24-29.
95. Rabbani S.A., Harakidas P., Guo Y., Steinman D., Davidsen S.K., Morgan D.W. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of prostate cancer in vivo. Int. J. Cancer. 87:2000;276-282.
96. Rubin M.A., Buyyounouski M., Bagiella E., Sharir S., Neugut A., Benson M., de la Taille A., Katz A.E., Olsson C.A., Ennis R.D. Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology. 53:1999;542-547.
97. Russell P.J., Bennett S., Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem. 44:1998;705-723.
98. Schröder F.H. Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int. 83:1999;161-170.
99. Silberman M.A., Partin A.W., Veltri R.W., Epstein J.I. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:1997;772-779.
100. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA. 92:1995;4562-4566.
101. Small E.J., Meyer M., Marshall M.E., Reyno L.M., Meyers F.J., Natale R.B., Lenehan P.F., Chen L., Slichenmeyer W.J., Eisenberger M. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J. Clin. Oncol. 18:2000;1440-1450.
102. Smith D.C., Pienta K.J. Paclitaxel in the treatment of hormone-refractory prostate cancer. Sem. Oncol. 26:(Suppl. 2):1999;109-111.
103. Stearns M.E., Garcia F.U., Fudge K., Rhim J., Wang M. Role of interleukin 10 and transforming growth factor β1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin. Cancer Res. 5:1999;711-720.
104. Steward W.P. Marimastat (BB2516): current status of development. Cancer Chemother. Pharmacol. 43:1999;S56-S60.
105. Stewart R.J., Panigrahy D., Flynn E., Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol. 165:2001;688-693.
106. Strohmeyer D., Rössing C., Strauss F., Bauerfeind A., Kaufmann O., Loening S. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate. 42:2000a;26-33.
107. Strohmeyer D., Rössing C., Bauerfeind A., Kaufmann O., Schlechte H., Bartsch G., Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate. 45:2000b;216-224.
108. Sugamoto T., Tanji N., Sato K., Fujita H., Nishio S., Sakanaka M., Yokoyama M. The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization. Anticancer Res. 21:2001;77-88.
109. Tuxhorn J.A., Ayala G.E., Rowley D.R. Reactive stroma in prostate cancer progression. J. Urol. 166:2001;2472-2483.
110. Van Moorselaar R.J.A., van Stratum P., Borm G., Debruyne F.M.J., Schalken J.A. Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. Prostate. 18:1991;331-344.
111. Vartanian R.K., Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab. Invest. 73:1995;844-850.
112. Vukanovic J., Isaacs J.T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic tumors. Cancer Res. 55:1995;1499-1504.
113. Walsh P.C., Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J. Urol. 128:1982;492-497.
114. Walsh K., Sherwood R.A., Dew T.K., Mulvin D. Angiogenic peptides in prostatic disease. BJU Int. 84:1999;1081-1083.
115. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143:1993;401-409.
116. Wood M., Fudge K., Mohler J.L., Frost A.R., Garcia F., Wang M., Stearns M.E. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis. 15:1997;246-258.
117. Wurmbach J.-H., Hammerer P., Sevinc S., Huland H., Ergün S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 20:2000;5217-5220.
118. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., Yoshimura N., Hla T., Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 89:2000;589-596.
119. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835.
120. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.-M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545.
121. Zhu X., Humphrey P.A. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology. 56:2000;1071-1074.